Golseek-1: A Phase 3, double-blind, randomized study of golcadomide (GOLCA), a potential, first-in-class, oral CELMoD™ agent, + R-CHOP vs placebo + R-CHOP in patients with previously untreated, high-risk, large B-cell lymphoma
Authors
Maria Bouzani
Marc Hoffmann (ORCID: https://orcid.org/0000-0003-2166-3105)
Golseek-1: A Phase 3, double-blind, randomized study of golcadomide (GOLCA), a potential, first-in-class, oral CELMoD™ agent, + R-CHOP vs placebo + R-CHOP in patients with previously untreated, high-risk, large B-cell lymphoma
Maria Bouzani, Marc Hoffmann, Serena Perna, Jason R. Westin et al.
Journal
Blood
Topics
Lymphoma Diagnosis and Treatment
article
Golseek-1: A Phase 3, double-blind, randomized study of golcadomide (GOLCA), a potential, first-in-class, oral CELMoD™ agent, + R-CHOP vs placebo + R-CHOP in patients with previously untreated, high-risk, large B-cell lymphoma
Maria Bouzani, Marc Hoffmann, Serena Perna, Jason R. Westin, Juan Miguel Bergua Burgués, Michał Kwiatek, Keshu Zhou, Alejandro Berkovits, Floriane Boucaud, Grzegorz S. Nowakowski, Theodoros P. Vassilakopoulos, Arpankumar Patel, Sung Yong Oh, Huiqiang Huang, Tai‐Chung Huang, Ou Bai, Ichiro Kawashima, Javier Muñoz, Argyrios Gkasiamis, Wojciech J. Jurczak, Adrien Petel
article en
Abstract
No abstract available for this paper.
Publication Tag
BloodVol. 146(Supplement 1)
Institutions
Poznan University of Medical Sciences (PL), Toyota Motor Corporation (Switzerland) (CH), The University of Texas MD Anderson Cancer Center (US), Bristol-Myers Squibb (Germany) (DE), Sun Yat-sen University (CN), BioClinica (United States) (US), Jilin University (CN), Zhengzhou University (CN), Hospital San Pedro de Alcántara (ES), Laiko General Hospital of Athens (GR), National Institute of Oncology (HU), First Hospital of Jilin University (CN), University of Kansas Medical Center (US), National Taiwan University Hospital (TW), Bristol-Myers Squibb (Sweden) (SE), National Science Centre (PL), Sun Yat-sen University Cancer Center (CN), Krakow Cardiovascular Research Institute (PL), TOCA at Banner Health (US), Evangelismos Hospital (GR), Bristol-Myers Squibb (Switzerland) (CH), Dong-A University (KR), University of Yamanashi (JP)